Please login to the form below

Not currently logged in
Email:
Password:

orphan diseases

This page shows the latest orphan diseases news and features for those working in and with pharma, biotech and healthcare.

Celgene bulks up pipeline again with $2.1bn Prothena deal

Celgene bulks up pipeline again with $2.1bn Prothena deal

smaller $101m collaboration with Vividion Therapeutics that also covers cancer and inflammatory diseases targets. ... Our collaboration leverages each company’s core expertise in protein homeostasis and protein clearance to target proteins that are the

Latest news

More from news
Approximately 3 fully matching, plus 119 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    During 2016, special approval procedures like conditional and accelerated approval pathways were issued for seven of the new approvals in the EU, the majority in oncology and for orphan diseases. ... We expect the strong overall trend for more orphan

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Rare diseases: meeting the challenge. Problems with regulating orphan drugs. The European Medicines Agency estimates that 30 million people living in the European Union suffer from a rare disease. ... Numbers game. The number of orphan drugs actually

  • Deal Watch February 2017 Deal Watch February 2017

    IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior therapies for metastatic disease and also has Fast Track status and orphan designation ... The amendment gives Vifor the rights to

  • A rare talent A rare talent

    A rare challenge. That knowledge is currently focused on bringing new treatments to market for rare diseases and working to ensure the environment for orphan drugs is fit-for-purpose, twin ... At the forefront of his mind is the position of access to

  • Mastering the rare disease challenge Mastering the rare disease challenge

    Mastering the rare disease challenge. Identifying expertise and customising communication in orphan drug marketing. ... Orphan drugs are few and far between. Long awaited by patients and physicians, it should be an easy job to market them.

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics